Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms. These symptoms range from mild breathing problems to life-threatening problems or death. Some people have no symptoms. This study aims to learn how acute and late immune responses to COVID-19 lead to different outcomes. The immune system is the body s defense against germs, including viruses, that invade the body. Objective: To characterize the immune responses during and after SARS-CoV-2 infection and determine if there is any relationship to clinical course and outcome. Eligibility: People ages 0 99 who have confirmed or suspected SARS-CoV-2 infection, people who are not infected despite heavy exposure, and relatives of enrolled participants. Design: This is a sample collection protocol to receive send-in biological specimens for exploratory studies, including gene testing. Participants will not be seen at the NIH for study visits. Study staff will talk with participants health care providers to screen them for the study. Participants enrolled into the protocol will send samples and clinical information at least once and more often if the participant has COVID-19. All participants will provide blood samples and possibly stool. We may also ask for left over specimens from any medical procedures completed as part of medical care. The study staff will also request participants health care providers to complete a survey to collect demographic and medical data. Some of this information may need to be provided directly by the participant. Pregnant individuals are invited to participate and may be asked to give cord blood samples after delivery. Study findings that affect participants health may be shared with their health care provider. Depending on findings, participants may be contacted to take part in other NIH studies.
In response to the public health emergency posed by the coronavirus disease 2019 (COVID-19)
pandemic, researchers at the National Institute of Allergy and Infectious Diseases (NIAID)
are leading a large international collaboration to characterize the innate and adaptive
immune responses to acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection and convalescence. This protocol will allow the NIAID Laboratory of Clinical
Immunology and Microbiology (LCIM) to remotely enroll participants for send-in sample
collection for analyses to characterize the immune response to SARS-CoV-2, better enabling
the LCIM to support NIAID s commitment to safeguarding the health of Americans and people
around the world by accelerating research efforts to characterize SARS CoV 2. This is a
prospective sample collection protocol to receive send in biological samples (e.g., blood,
saliva, stool, and leftover clinically collected samples) for exploratory studies to
characterize the immune response to COVID 19. Participants will not be seen at the NIH for
study visits. Under this protocol, samples will be collected longitudinally from up to 300
patients with confirmed or suspected SARS CoV 2 infection and sent to the NIH for research
evaluations. Additionally, samples will be collected from up to 200 uninfected patients and
patient relatives. Testing will be performed to improve understanding of host immune
responses to COVID-19, including but not limited to genetic, molecular, and proteomic
testing. Findings relevant to participants health and medical care may be returned to them
and their referring health care providers or study teams.
- INCLUSION CRITERIA:
Participants enrolled onto this protocol must meet all of the following criteria:
1. Aged 0-99 years (including viable neonates).
2. Meets one of the following criteria:
1. Patient with a known or suspected diagnosis of SARS-CoV-2 infection (past or
current), typically but not always supported by a positive PCR test for viral
RNA;
2. Individual who has remained uninfected with negative SARS-CoV-2 serologies
despite heavy or extensive COVID-19 exposure in the workplace or home
environment; or
3. Biological relative of a participant being studied under this protocol. Relatives
may be biological mother, father, siblings, children, grandparents, aunts,
uncles, or first cousins.
3. For individuals considered for enrollment as uninfected individuals and biological
relatives, able to provide informed consent.
4. Willing to allow genetic testing.
5. Willing to allow storage of samples and data for future research.
EXCLUSION CRITERIA:
Individuals meeting any of the following criteria will be excluded from study
participation:
1. Any condition that, in the opinion of the investigator, contraindicates participation in
this study.
Since patients can be concurrently infected with multiple respiratory viruses, positive
testing for other viruses such as rhinovirus, influenza virus, etc., does not exclude an
individual from study participation where there remains a high clinical suspicion of
COVID-19 infection despite negative testing for SARS-CoV-2.
Co-enrollment guidelines: Participants may be co-enrolled in other studies; however, study
staff should be notified of co-enrollment.
Niaid/Lcim
Rockville, Maryland, United States
Investigator: Helen Su, M.D. Ph. D
Contact: 301-451-8783
hsu@niaid.nih.gov
Margaret A Abaandou
(301) 761-7627
margaret.abaandou@nih.gov
Helen C Su, M.D.
(301) 451-8783
hsu@mail.nih.gov
Helen C Su, M.D., Principal Investigator
National Institute of Allergy and Infectious Diseases (NIAID)